Breast Lesion Localization Market

Breast Lesion Localization Market by Type (Wire, Radioisotope (ROLL,RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy,Lumpectomy), End User Preference Survey (Selection Criteria, Replacement Trend) (2022 - 2026)

Report Code: MD 4236 Jan, 2022, by marketsandmarkets.com

[238 Pages Report] The breast lesion localization market is expected to reach USD 305 million by 2026 from USD 244 million in 2021, will grow at a CAGR of 4.6% during the forecast period. The market is primarily driven by the increasing number of breast cancer screening programs, and improved reimbursement scenario. The localization of breast lesions is a common procedure that has evolved as a surgical, imaging, and biomedical technology. Wire guided localization method was introduced years ago and was the first technique introduced to help localize non-palpable image-guided breast lesions.

Breast Lesion Localization Methods Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Breast lesion localization Market

The impact of the COVID-19 pandemic and the lockdown is clearly visible in various industries, including the market. The breast biopsy market witnessed a loss of business, and the trend continued till December 2020. The global market experienced a short-term negative growth in 2020. Major regulatory authorities across the globe (such as the CDC, the WHO, the MHRA, the TGA, and the EMA) have identified that breast cancer patients are at greater risk of COVID-19 infection than healthy adults. caregivers and hospitals are expected to witness delays in elective surgeries, screening procedures, and the number of breast lesion localization procedures. However, the market started gradually rising from the late second half of 2020 owing to the increase in the number of biopsies resulting from clearing backlog as well as new cases and fully re-opened healthcare services. In 2021, with the launch of the vaccine against the COVID-19 virus, the patients' options for elective surgeries increased.

Breast Lesion Localization market Dynamics

Drivers: Increasing incidence of breast cancer

Breast cancer is among the most common diseases affecting women in developed and developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe. Globally, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries, such as breast enhancement.

Growing rate of the aging population

With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors (a type of adult stem cell at the root of many breast cancers) and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. According to the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. In contrast, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

Restraints: Uncertainty in regulatory approval procedures

Regulatory agencies such as the US FDA require comprehensive clinical data supporting the clinical safety and efficacy of a product under approval. With the presence of stringent regulatory requirements for product approval, players operating in the breast lesion localization methods (specially radioisotope localization) market need to obtain nuclear regulatory clearance from the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. This approval process is very lengthy and capital-intensive, which makes it difficult for small manufacturers and companies with limited budgets to sustain themselves in this market.

Opportunities: Emerging economies offer high growth potential

Developing economies, such as India, China, Brazil, South Korea, Turkey, Russia, and South Africa, offer high growth opportunities for the major players operating in the breast lesion localization market. A large population base—especially in India and China—offers a sustainable market for entire medical and surgical devices. As per GLOBOCAN 2020, the incidence of breast cancer in China is estimated to be 416,000 in 2020; this number is estimated to increase by 446,000 cases by 2025. Likewise, the number of women diagnosed with breast cancer is estimated to reach 272,000 in 2040 from 178,000 in 2020 in India. Breast cancer incidence among women aged more than 65 is expected to increase by ~61% and ~65% in India and China, respectively, by 2025.

Governments in emerging countries are also investing heavily in the development and modernization of healthcare infrastructure. For instance, According to the OECD Data, the healthcare spending of China in 2020 was 810.8 USD/Capita. Likewise, according to Health Expenditure and Financing data, Brazil spent ~9.5% of its GDP on healthcare in 2020. The Ministry of Health in Brazil and several non-governmental organizations have also initiated efforts to improve early diagnosis and to promote breast cancer screening and education in the country.

Challenges: Shortage of oncologists

To achieve better outcomes, breast cancer surgeries and lesion localization procedures are performed by skilled professionals. These surgeries are considered to involve more risks when compared to other surgeries because of various challenges, such as the localization of tumors, risk of healthy tissue excision, lymphedema, and seroma. Similarly, the use of radioactive materials may increase a patient’s risk of developing radiation-induced cancer. Exposure to radiation has several short-term and long-term side effects, which usually occur within six months or even after a year of exposure. Some of the common side-effects after radiation exposure are mild pain or discomfort around the breast, skin damage, swelling or inflammation of the breast or surrounding tissues, loss of hair in the armpit or chest, and fatigue. Moreover, radiation exposure can also lead to the damage of nerves in the arm, hand, or chest. To reduce such risks, localization procedures require trained operators and radiologists, who are required to go through a certification process to perform breast lesion localization.

North America is expected to account for the largest share of the Breast lesion localization market in 2020

Breast Lesion Localization Methods Market by Region

To know about the assumptions considered for the study, download the pdf brochure

In terms of volume, North America accounted for the largest share of the breast lesion localization market is 2020, followed by Europe. The APAC market is projected to grow at the highest CAGR during the forecast period. Growth in this market can primarily be attributed to the improving healthcare infrastructure, rising government spending on breast cancer research, and increasing awareness about the importance of the early detection of breast cancer in several APAC countries.

Key Market Players breast lesion localization market are Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada). Other players in the market are Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

Scope of the Market

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

By type and By Usage

Geographies covered

North America, Europe, Asia Pacific, RoW

Companies covered

Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada). Other players in the market are Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

The study categorizes the breast lesion localization market based on type, usage and regional & global level.

Global Breast lesion localization Market, by Type

  • Wire Localization
  • Radioisotope Localization
    • Radioguided Occult Lesion Localization
    • Radioactive Seed Localization
  • Magnetic Localization
  • Electromagnetic Localization
  • Other Localization Methods

Global Breast lesion localization Market, by Usage

  • Breast Biopsy
  • Breast Conservation (Lumpectomy)

Global Breast lesion localization Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of World

Recent Developments

  • In January 2021, Hologic Inc. has completed the acquisition of Somatex Medical Technologies, which will enable Hologic Inc to strengthen their breast marker portfolio.
  • In October 2020, Endomagnetics Ltd. launched a product named Magseed, which is implanted in the affected breast prior to the surgery, and through the use of a probe, can point out to the surgeon where exactly the cancerous tissue is located.
  • In January 2019, IZI acquired Cook’s product portfolio of soft-tissue biopsy and breast localization needles. This will enable IZI to capture newer markets.
  • In November 2018, Merit Medical Systems Inc. has completed the acquisition of Cianna Medical Inc. and its breast cancer localization and guidance devices, which adds to Merit, a technology leader in breast tumor localization.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.4 SCOPE OF THE STUDY
           1.4.1 MARKETS COVERED
                    FIGURE 1 GLOBAL BREAST LESION LOCALIZATION MARKET
           1.4.2 YEARS CONSIDERED FOR THE STUDY
    1.5 CURRENCY
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
    2.2 MARKET SIZE ESTIMATION
          FIGURE 6 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION:
          FIGURE 8 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: BREAST LESION LOCALIZATION MARKET (2020)
          FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MARKET (2021–2026)
          FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
          FIGURE 11 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
          FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
          TABLE 1 RISK ASSESSMENT: BREAST LESION LOCALIZATION MARKET
    2.7 LIMITATIONS
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 13 BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021 VS. 2026 (THOUSAND PROCEDURES)
    FIGURE 14 GLOBAL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021 VS. 2026 (THOUSAND PROCEDURES)
    FIGURE 16 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 GLOBAL MARKET, BY USAGE, 2021 VS. 2026 (THOUSAND PROCEDURES)
    FIGURE 18 GLOBAL MARKET, BY USAGE, 2021 VS. 2026 (USD MILLION)
    FIGURE 19 GEOGRAPHIC ANALYSIS: GLOBAL MARKET (BASED ON PROCEDURE)
    FIGURE 20 GEOGRAPHIC ANALYSIS: GLOBAL MARKET (BASED ON VALUE)

4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 BREAST LESION LOCALIZATION MARKET OVERVIEW
          FIGURE 21 RISING AWARENESS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: MARKET, BY TYPE
          FIGURE 22 WIRE LOCALIZATION TO HOLD THE LARGEST SHARE OF THE ASIA PACIFIC BREAST LESION LOCALIZATION MARKET IN 2020
    4.3 GLOBAL MARKET (BASED ON VALUE): GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 23 APAC COUNTRIES TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL MARKET DURING THE FORECAST PERIOD
    4.4 GLOBAL , BY REGION
          FIGURE 24 NORTH AMERICA TO DOMINATE THE GLOBAL MARKET TILL 2026
    4.5 GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS (THOUSAND PROCEDURES)
          FIGURE 25 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 61)
    5.1 MARKET DYNAMICS
          FIGURE 26 BREAST LESION LOCALIZATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 MARKET DRIVERS
                    5.1.1.1 Increasing incidence of breast cancer
                                TABLE 2 TOP 10 COUNTRIES WITH THE HIGHEST INCIDENCE OF BREAST CANCER, 2020
                                FIGURE 27 ESTIMATED GLOBAL NUMBER OF NEW CASES OF BREAST CANCER FROM 2020–2040
                    5.1.1.2 Growing rate of the aging population
                    5.1.1.3 Increasing awareness on the early detection of breast cancer
           5.1.2 MARKET RESTRAINTS
                    5.1.2.1 Uncertainty in regulatory approval procedures
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Emerging economies offer high growth potential
                    5.1.3.2 Increasing adoption of technologically advanced localization procedures
           5.1.4 CHALLENGES
                    5.1.4.1 Shortage of oncologists

6 INDUSTRY INSIGHTS (Page No. - 68)
    6.1 INDUSTRY TRENDS
           6.1.1 ELECTROMAGNETIC WAVES FOR THE LOCALIZATION OF BREAST LESIONS
           6.1.2 RADIOFREQUENCY IDENTIFICATION IN BREAST LESION LOCALIZATION
           6.1.3 MACHINE LEARNING ALGORITHMS FOR COMPUTER-AIDED BREAST LESION DETECTION
    6.2 IMPACT OF COVID-19 ON THE BREAST LESION LOCALIZATION MARKET: RESTRUCTURING OF BREAST CANCER CARE
    6.3 VALUE CHAIN ANALYSIS
    6.4 REIMBURSEMENT ANALYSIS
          TABLE 3 MEDICARE REIMBURSEMENT FOR BREAST LESION LOCALIZATION METHODS
    6.5 TECHNOLOGY ANALYSIS
           6.5.1 KEY TECHNOLOGIES
                    6.5.1.1 Wire guided localization (WL)
                    6.5.1.2 Carbon making
                    6.5.1.3 Radio-guided occult lesion localization (ROLL)
                    6.5.1.4 Radioactive seed localization (RSL)
                    6.5.1.5 Magnetic seed localization (MSL)
                    6.5.1.6 Radio frequency reflector (RFR)
           6.5.2 COMPLEMENTARY TECHNOLOGIES
                    6.5.2.1 Mammography
                    6.5.2.2 3D Mammography or Tomosynthesis
                    6.5.2.3 Magnetic resonance imaging
                    6.5.2.4 Ultrasound
           6.5.3 ADJACENT TECHNOLOGIES
                    6.5.3.1 Computer vision and artificial intelligence
    6.6 PORTER’S FIVE FORCES ANALYSIS
          TABLE 4 BREAST LESION LOCALIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.6.1 INTENSITY OF COMPETITIVE RIVALRY
           6.6.2 BARGAINING POWER OF SUPPLIERS
           6.6.3 BARGAINING POWER OF BUYERS
           6.6.4 THREAT OF SUBSTITUTES
           6.6.5 THREAT OF NEW ENTRANTS
    6.7 REGULATORY ANALYSIS
           6.7.1 NORTH AMERICA
                    6.7.1.1 US
                                TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
                                TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    6.7.1.2 Canada
                                TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                                TABLE 8 BREAST LESION LOCALIZATION DEVICES CLASSIFICATION ACCORDING TO THE GOVERNMENT OF CANADA
           6.7.2 EUROPE
                    FIGURE 28 EUROPE: CLASS III MEDICAL DEVICES
           6.7.3 ASIA PACIFIC
                    6.7.3.1 India
    6.8 PATENT ANALYSIS
           6.8.1 PATENT PUBLICATION TRENDS FOR BREAST LESIONS
                    FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021)
           6.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR BREAST LESION PATENTS (JANUARY 2011–DECEMBER 2021)
                    FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR BREAST LESION PATENTS (JANUARY 2011–DECEMBER 2021)

7 BREAST LESION LOCALIZATION MARKET, BY TYPE (Page No. - 85)
    7.1 INTRODUCTION
          TABLE 9 GLOBAL MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 10 GLOBAL MARKET, BY TYPE, 2019–2026 (USD MILLION)
    7.2 COVID-19 IMPACT ON THE GLOBAL MARKET, BY TYPE
    7.3 WIRE LOCALIZATION
           7.3.1 WIRE LOCALIZATION SEGMENT TO COMMAND THE LARGEST SHARE OF THE GLOBAL MARKET
                    TABLE 11 WIRE LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 12 WIRE LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 RADIOISOTOPE LOCALIZATION
          TABLE 13 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 14 RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 15 RADIOISOTOPE LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 16 RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.4.1 RADIOGUIDED OCCULT LESION LOCALIZATION (ROLL)
                    7.4.1.1 ROLL to result in shorter operating times, higher rates of tumor-free margins, and lower rates of re-operation
                                TABLE 17 RADIOGUIDED OCCULT LESION LOCALIZATION MARKET, BY COUNTRY,  2019–2026 (THOUSAND PROCEDURES)
                                TABLE 18 RADIOGUIDED OCCULT LESION LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.4.2 RADIOACTIVE SEED LOCALIZATION (RSL)
                    7.4.2.1 Reduction in re-excision rates, decreased operative time, and long half-life of RSL to drive market growth
                                TABLE 19 RADIOACTIVE SEED LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                                TABLE 20 RADIOACTIVE SEED LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 MAGNETIC LOCALIZATION
           7.5.1 MAGNETIC LOCALIZATION TECHNIQUE TO INCREASE WORKFLOW EFFICIENCY AND COST-EFFECTIVENESS, ELIMINATE ISSUES RELATED TO NONRADIOACTIVE TECHNOLOGY, AND IMPROVE SURGICAL PLANNING
                    TABLE 21 MAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 22 MAGNETIC LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 ELECTROMAGNETIC LOCALIZATION
           7.6.1 ELECTROMAGNETIC LOCALIZATION TO MAKE SMALLER INCISIONS TO BE MORE PRECISE AND SAVE MORE OF THE NORMAL TISSUE DURING SURGERIES
                    TABLE 23 ELECTROMAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 24 ELECTROMAGNETIC LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 OTHER LOCALIZATION METHODS
          TABLE 25 OTHER LOCALIZATION METHODS MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 26 OTHER LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 BREAST LESION LOCALIZATION MARKET, BY USAGE (Page No. - 103)
    8.1 INTRODUCTION
          TABLE 27 GLOBAL MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 28 GLOBAL MARKET, BY USAGE, 2019–2026 (USD MILLION)
    8.2 BREAST BIOPSY
           8.2.1 BREAST BIOPSY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BREAST LESION LOCALIZATION MARKET BY USAGE
                    TABLE 29 GLOBAL MARKET FOR BREAST BIOPSY, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 30 GLOBAL MARKET FOR BREAST BIOPSY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 BREAST CONSERVATION (LUMPECTOMY)
           8.3.1 INCREASING ADOPTION OF BREAST CONSERVATION THERAPY TO DRIVE THE GROWTH OF BREAST LESION LOCALIZATION MARKET
                    TABLE 31 GLOBAL MARKET FOR BREAST CONSERVATION, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 32 GLOBAL MARKET FOR BREAST CONSERVATION, BY COUNTRY, 2019–2026 (USD MILLION)

9 BREAST LESION LOCALIZATION MARKET, BY REGION (Page No. - 110)
    9.1 INTRODUCTION
          FIGURE 32 NUMBER OF BREAST CANCER CASES VS NUMBER OF DEATHS IN 2020 (IN THOUSANDS)
          TABLE 33 GLOBAL MARKET, BY REGION, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 34 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 33 NORTH AMERICA: NUMBER OF BREAST CANCER CASES 2020 (IN THOUSANDS)
          TABLE 35 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 36 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 37 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 38 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 39 NORTH AMERICA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 40 NORTH AMERICA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 41 NORTH AMERICA: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 42 NORTH AMERICA: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.2.1 US
                    TABLE 43 US: KEY MACROINDICATORS
                    TABLE 44 US: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 45 US: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 46 US: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 47 US: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 48 US: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 49 US: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.2.2 CANADA
                    TABLE 50 CANADA: KEY MACROINDICATORS
                    TABLE 51 CANADA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 52 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 53 CANADA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 54 CANADA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 55 CANADA: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 56 CANADA: MARKET, BY USAGE, 2019–2026 (USD MILLION)
    9.3 EUROPE
          FIGURE 35 EUROPE: NUMBER OF BREAST CANCER CASES, 2020 (IN THOUSANDS)
          TABLE 57 EUROPE: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 58 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 59 EUROPE: MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 60 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 61 EUROPE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 62 EUROPE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 63 EUROPE: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 64 EUROPE: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.3.1 GERMANY
                    TABLE 65 GERMANY: KEY MACROINDICATORS
                    TABLE 66 GERMANY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 67 GERMANY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 68 GERMANY: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 69 GERMANY: RADIOISOTOPE LOCALIZATION METHODS MARKET,  BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 70 GERMANY: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 71 GERMANY: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.3.2 FRANCE
                    TABLE 72 FRANCE: KEY MACROINDICATORS
                    TABLE 73 FRANCE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 74 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 75 FRANCE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 76 FRANCE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 77 FRANCE: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 78 FRANCE: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.3.3 UK
                    TABLE 79 UK: KEY MACROINDICATORS
                    TABLE 80 UK: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 81 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 82 UK: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 83 UK: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 84 UK: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 85 UK: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.3.4 ITALY
                    TABLE 86 ITALY: KEY MACROINDICATORS
                    TABLE 87 ITALY: MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 88 ITALY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 89 ITALY: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 90 ITALY: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 91 ITALY: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 92 ITALY: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.3.5 SPAIN
                    TABLE 93 SPAIN: KEY MACROINDICATORS
                    TABLE 94 SPAIN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 95 SPAIN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 96 SPAIN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 97 SPAIN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 98 SPAIN: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 99 SPAIN: MARKET, BY USAGE,  2019–2026 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 100 ROE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 101 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 102 ROE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 103 ROE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 104 ROE: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 105 ROE: MARKET, BY USAGE, 2019–2026 (USD MILLION)
    9.4 ASIA PACIFIC
          FIGURE 37 APAC: NUMBER OF BREAST CANCER CASES, 2020 (IN THOUSANDS)
          TABLE 106 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 107 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 108 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 109 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 110 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 111 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 112 ASIA PACIFIC: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 113 ASIA PACIFIC: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.4.1 CHINA
                    TABLE 114 CHINA: KEY MACROINDICATORS
                    TABLE 115 CHINA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 116 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 117 CHINA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 118 CHINA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 119 CHINA: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 120 CHINA: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.4.2 JAPAN
                    TABLE 121 JAPAN: KEY MACROINDICATORS
                    TABLE 122 JAPAN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 123 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 124 JAPAN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 125 JAPAN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 126 JAPAN: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 127 JAPAN: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    TABLE 128 INDIA: KEY MACROINDICATORS
                    TABLE 129 INDIA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 130 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 131 INDIA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 132 INDIA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 133 INDIA: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 134 INDIA: MARKET, BY USAGE, 2019–2026 (USD MILLION)
           9.4.4 REST OF APAC
                    TABLE 135 ROAPAC: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 136 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 137 ROAPAC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 138 ROAPAC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 139 ROAPAC: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
                    TABLE 140 ROAPAC: MARKET, BY USAGE, 2019–2026 (USD MILLION)
    9.5 REST OF THE WORLD
          TABLE 141 ROW: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 142 ROW: MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 143 ROW: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 144 ROW: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 145 ROW: MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES)
          TABLE 146 ROW: MARKET, BY USAGE, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 181)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES
     10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 39 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE BREAST LESION LOCALIZATION MARKET
     10.4 MARKET SHARE ANALYSIS
             FIGURE 40 GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     10.5 COMPANY EVALUATION QUADRANT
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                       FIGURE 41 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION QUADRANT (2020)
     10.6 COMPANY EVALUATION QUADRANT FOR START-UPS
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 DYNAMIC COMPANIES
             10.6.3 STARTING BLOCKS
             10.6.4 RESPONSIVE COMPANIES
                       FIGURE 42 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)
     10.7 COMPANY PRODUCT FOOTPRINT
             TABLE 147 PRODUCT PORTFOLIO ANALYSIS: GLOBAL MARKET
     10.8 GEOGRAPHIC FOOTPRINT OF THE MAJOR PLAYERS IN THE GLOBAL MARKET
             TABLE 148 GEOGRAPHIC REVENUE MIX: GLOBAL MARKET (2020)
     10.9 COMPETITIVE SCENARIO
             10.9.1 DEALS
                        TABLE 149 DEALS
             10.9.2 PRODUCT LAUNCHES AND UPGRADES
                        TABLE 150 PRODUCT LAUNCHES AND UPGRADES
     10.10 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS
     10.11 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS
     10.12 BREAST LESION LOCALIZATION METHODS: SELECTION CRITERIA EVALUATION
     10.13 QUALITATIVE ASSESSMENT OF REPLACEMENT TRENDS

11 COMPANY PROFILES (Page No. - 196)
     11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             11.1.1 HOLOGIC, INC.
                        TABLE 151 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
             11.1.2 BECTON, DICKINSON AND COMPANY
                        TABLE 152 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             11.1.3 MERIT MEDICAL SYSTEMS
                        TABLE 153 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW
                        FIGURE 48 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2020)
             11.1.4 LEICA BIOSYSTEMS NUSSLOCH GMBH
                        TABLE 154 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.5 ARGON MEDICAL DEVICES
                        TABLE 155 ARGON MEDICAL DEVICES: BUSINESS OVERVIEW
             11.1.6 LAURANE MEDICAL LLC
                        TABLE 156 LAURANE MEDICAL LLC: BUSINESS OVERVIEW
             11.1.7 ENDOMAGNETICS LTD. (ENDOMAG)
                        TABLE 157 ENDOMAGNETICS LIMITED: BUSINESS OVERVIEW
             11.1.8 INTRAMEDICAL IMAGING, LLC
                        TABLE 158 INTRAMEDICAL IMAGING, LLC: BUSINESS OVERVIEW
             11.1.9 ISOAID
                        TABLE 159 ISOAID: BUSINESS OVERVIEW
             11.1.10 SURGICEYE GMBH
                        TABLE 160 SURGICEYE GMBH: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS
             11.2.1 RANFAC CORP.
                        TABLE 161 RANFAC CORP.: BUSINESS OVERVIEW
             11.2.2 MERMAID MEDICAL GROUP
                        TABLE 162 MERMAID MEDICAL GROUP: BUSINESS OVERVIEW
             11.2.3 IZI MEDICALPRODUCTS, LLC
                        TABLE 163 IZI MEDICAL PRODUCTS, LLC: BUSINESS OVERVIEW
             11.2.4 MATEK MEDIKAL
                        TABLE 164 MATEK MEDIKAL: BUSINESS OVERVIEW
             11.2.5 TSUNAMI MEDICAL SRL
                        TABLE 165 TSUNAMI MEDICAL SRL: BUSINESS OVERVIEW
             11.2.6 BPB MEDICA
                        TABLE 166 BPB MEDICA: BUSINESS OVERVIEW
             11.2.7 SIRIUS MEDICAL SYSTEMS B.V.
                        TABLE 167 SIRIUS MEDICAL SYSTEMS B.V.: BUSINESS OVERVIEW
             11.2.8 MOLLI SURGICAL INC.
                        TABLE 168 MOLLI SURGICAL INC.: BUSINESS OVERVIEW
             11.2.9 STERYLAB S.R.L.
                        TABLE 169 STERYLAB S.R.L.: BUSINESS OVERVIEW
             11.2.10 CP MEDICAL
                        TABLE 170 CP MEDICAL: BUSINESS OVERVIEW
             11.2.11 MDL SRL
                        TABLE 171 MDL SRL: BUSINESS OVERVIEW
             11.2.12 BIOMEDICAL SRL
                        TABLE 172 BIOMEDICAL SRL: BUSINESS OVERVIEW
             11.2.13 ELUCENT MEDICAL
                        TABLE 173 ELUCENT MEDICAL: BUSINESS OVERVIEW
             11.2.14 VIGEO SRL
                        TABLE 174 VIGEO SRL: BUSINESS OVERVIEW
             11.2.15 MEDAX MEDICAL DEVICES
                        TABLE 175 MEDAX MEDICAL DEVICES: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 232)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 RELATED REPORTS
     12.4 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the breast lesion localization market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.

A breakdown of the primary respondents is provided below:

Breast Lesion Localization Methods Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the breast lesion localization market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Objectives of the Study

  • To define, describe, and forecast the breast lesion localization market based on type, usage, and region
  • To provide detailed information on the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details about the competitive landscape for market leaders
  • To forecast the size of market segments with respect to North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments (such as acquisitions, product launches, and agreements) in the breast lesion localization market
  • To evaluate the different parameters considered for the selection of breast lesion localization
  • To study end user preferences for different breast lesion localization methods as well as study the replacement trends and buying behavior of end users
  • To evaluate the impact of the COVID-19 pandemic on the breast lesion localization market across the globe

Available customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of each company

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the RoE breast lesion localization market into Switzerland, Sweden, and others
  • Further breakdown of the RoAPAC breast lesion localization market into Australia, South Korea, and others

Competitive Landscape Assessment

Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the breast lesion localization market

  • Competitive leadership mapping for established players in the US
Breast Lesion Localization Market Size,  Share & Growth Report
Report Code
MD 4236
Published ON
Jan, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status